加巴喷丁联合喹硫平治疗血管性痴呆叠加谵妄的对照研究被引量：4

A control study of combined gabapentin and quetiapine to treat delirium superimposed on vascular dementia

在线阅读下载PDF

导出

摘要目的：比较加巴喷丁联合喹硫平与单用喹硫平治疗血管性痴呆叠加谵妄的疗效与疗效指数（CGI －EI）。方法血管性痴呆叠加谵妄患者62例，随机分成治疗组（加巴喷丁联合喹硫平组，30例）和对照组（单用喹硫平组，32例），在治疗前及治疗后3、9、15天进行谵妄量表（DSS ）评分，在治疗前和治疗后15天进行智能精神状态检查表（MMSE）、日常生活评定量表（ADL）及临床疗效总评量表（CGI）评分。结果治疗组与对照组治疗血管性痴呆叠加谵妄均有效，疗效指数增高。与对照组比较，治疗组的 DSS 评分在治疗后3、9、15天时明显增高，差异有统计学意义（P ＜0．05或 P ＜0．01）；治疗后 MMSE 评分明显增高，CGI 严重程度评分（CGI －SI）明显降低，疗效总评（CGI －GI）明显降低，CGI －EI 明显增高，差异有统计学意义（P ＜0．05）；ADL 评分的差异无统计学意义（P ＞0．05）。结论在治疗血管性痴呆叠加谵妄时，加巴喷丁联合喹硫平较单用喹硫平控制谵妄症状快，疗效和疗效指数更高，且较为安全。 Objective To compare the efficacy and efficacy index （CGI -EI） of delirium superimposed on vascular dementia using combined gabapentin and quetiapine and quetiapine alone.Methods A total of 62 patients with delirium superimposed on vascular dementia were randomly divided into a control group receiving quetiapine alone （n =32） and a treatment group given combined gabapentin and quetiapine （n =30）.All patients underwent DSS assessment before and 3, 9, and 15 days after treatment.They were assessed according to MMSE, ADL and CGI scales before and 15 days after treatment.Results Both therapies could treat delirium superimposed on vascular dementia effectively, with high efficacy index.Compared with the control, the treatment group could result in remarkably increased DSS, MMSE and CGI -EI scores 3, 9 and 15 days after treatment （P 〈0.05 or P 〈0.01）, in contrast with significantly decreased CGI -SI and CGI -GI scores （P 〈0.05）.However, no statistical difference was seen as to ADL score between both groups （P 〈0.05）.Conclusions Combined gabapentin and quetiapine when applied for delirium superimposed on vascular dementia, controls delirium related symptoms faster and produces better efficacy and higher efficacy index, which can be safely used.

作者沈青峰李海玲孙秀媛王恒王广法龚广厚闾金杰

机构地区徐州市东方人民医院老年精神科

出处《徐州医学院学报》 CAS 2015年第3期155-157,共3页 Acta Academiae Medicinae Xuzhou

基金国家自然科学基金（30870797）

关键词加巴喷丁喹硫平血管性痴呆叠加谵妄 gabapentin quetiapine delirium superimposed on vascular dementia

分类号 R741.05 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献6

1Morandi A,Davis D,Fick DM,et al.Delirium superimposed on dementia strongly predicts worse outcomes in older rehabilitation inpatients[J].J Am Med Dir Assoc,2014,15(5):349-354.
2Boettger S,Passik S,Breitbart W.Treatment characteristics of de-lirium superimposed on dementia[J].Int Psychogeriatr,2011,23(10):1671-1676.
3Boettger S,Jenewein J,Breitbart W.Haloperidol,risperidone,olanzapine and aripiprazole in the management of delirium:A comparison of efficacy,safety,and side effects[J/OL].Palliat Support Care,2014,Sep 5:1-7.
4Maneeton B,Maneeton N,Srisurapanont M,et al.Quetiapine versus haloperidol in the treatment of delirium:a double-blind,randomized,controlled trial[J].Drug Des Devel Ther,2013,7:657-667.
5陈梓斌,吴原,刘晓菲,刘云,马美刚,刘秋弟,谭明会.加巴喷丁治疗不宁腿综合征的系统评价[J].中国循证医学杂志,2012,12(6):727-734. 被引量：17
6Paulson CM,Monroe T,Mion LC.Pain assessment in hospitalized older adults with dementia and delirium[J].J Gerontol Nurs,2014,40(6):10-15.

二级参考文献36

1Willis T. The London practice of physick. London: Thomas Basset and William Crook. 1685.
2Ekbom A. Restless legs: A clinical study. Acta Med Scand, 1945, 158(suppl): 1-123.
3Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med, 2003, 4(2): 101-119.
4Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med, 2005, 165(11): 1286-1292.
5Nomura T, Inoue Y, Kusumi M, et al. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord, 2008, 23(16): 2363-2369.
6Tan EK, Seah A, See SJ, et al. Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord, 2001, 16(3): 577-579.
7Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med, 2004, 5(3): 237-246.
8Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol, 2005, 4(8): 465-475.
9Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord, 2008, 23(16): 2267-2302.
10Conti CF, Oliveira MM, Valbuza JS, et al. Anticonvulsants to treat idiopathic restless legs syndrome: systematic review. Arq Neuropsiquiatr, 2008, 66(2b): 431-435.